…
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Zhongchao Inc is Nasdaq‑listed; publicly available disclosures offer limited clarity on its current core business, assets, and operations. Long‑term growth drivers are not well documented, so any potential exposure to China‑focused markets or industry consolidation is unclear and requires review of company filings.
Key investment risks include opaque disclosure, thin trading liquidity, uncertain financial condition, and potential corporate governance and regulatory risks common to small foreign‑listed issuers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -5.77M | 0.06M | -11.98M | -2.55M | -0.11M |
| Minority interest | -0.50M | -0.37M | -0.03M | -0.12M | 0.00M |
| Net income | -6.31M | -0.64M | -11.34M | -2.82M | 0.24M |
| Selling general administrative | 11.30M | 4.99M | 6.70M | 6.80M | 5.86M |
| Selling and marketing expenses | - | 4.01M | 6.71M | 2.10M | 3.14M |
| Gross profit | 4.83M | 8.91M | 8.51M | 6.36M | 9.44M |
| Reconciled depreciation | 0.32M | 0.43M | 0.92M | 0.73M | 0.70M |
| Ebit | -5.77M | -0.34M | -5.41M | -2.95M | -0.32M |
| Ebitda | -5.45M | 0.09M | -4.49M | -2.22M | 0.38M |
| Depreciation and amortization | 0.32M | 0.43M | 0.92M | 0.73M | 0.70M |
| Operating income | -6.19M | -0.34M | -13.28M | -2.95M | -0.32M |
| Other operating expenses | 17.57M | 16.21M | 32.72M | 17.11M | 16.62M |
| Interest expense | - | - | - | -0.29M | 0.21M |
| Tax provision | 0.05M | 0.34M | -0.67M | 0.27M | -0.35M |
| Interest income | 0.34M | 0.24M | 0.24M | 0.14M | 0.18M |
| Net interest income | 0.34M | 0.24M | 0.24M | 0.14M | 0.18M |
| Income tax expense | 0.05M | 0.34M | -0.67M | 0.27M | -0.35M |
| Total revenue | 11.37M | 15.86M | 19.43M | 14.15M | 16.30M |
| Total operating expenses | 11.02M | 9.25M | 21.80M | 9.31M | 9.76M |
| Cost of revenue | 6.54M | 6.95M | 10.92M | 7.79M | 6.86M |
| Total other income expense net | 0.42M | 0.40M | 1.31M | 0.40M | 0.21M |
| Net income from continuing ops | -5.81M | -0.27M | -11.31M | -2.82M | 0.24M |
| Net income applicable to common shares | - | - | - | - | 0.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 24.32M | 25.88M | 24.42M | 38.61M | 36.27M |
| Intangible assets | 0.01M | 0.01M | 0.02M | 1.22M | 0.38M |
| Other current assets | 0.16M | 0.26M | 0.27M | 0.07M | 0.05M |
| Total liab | 1.72M | 1.73M | 3.38M | 5.60M | 3.70M |
| Total stockholder equity | 18.63M | 20.84M | 18.01M | 29.93M | 32.57M |
| Other current liab | 0.82M | 0.51M | 0.92M | 3.15M | 3.45M |
| Common stock | 0.03M | 0.03M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.03M | 0.03M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -14.19M | -7.96M | -7.27M | 4.12M | 7.18M |
| Good will | - | - | 0.00M | 5.77M | - |
| Other assets | - | - | - | - | 2.71M |
| Cash | 8.10M | 7.84M | 7.55M | 11.52M | 13.91M |
| Total current liabilities | 1.53M | 1.53M | 2.68M | 4.17M | 3.59M |
| Current deferred revenue | 0.15M | 0.20M | 0.84M | 0.40M | 0.01M |
| Net debt | -8.07M | -7.78M | -6.74M | -9.82M | -13.71M |
| Short term debt | 0.03M | 0.03M | 0.24M | 0.48M | 0.09M |
| Short long term debt total | 0.03M | 0.06M | 0.81M | 1.70M | 0.20M |
| Other stockholder equity | 34.48M | 29.06M | 25.13M | 25.00M | 22.99M |
| Property plant equipment | - | - | - | - | 4.13M |
| Total current assets | 16.96M | 18.71M | 18.71M | 22.70M | 27.25M |
| Long term investments | 1.23M | 1.09M | 1.31M | 1.26M | 2.14M |
| Net tangible assets | - | - | - | - | 32.54M |
| Short term investments | 5.82M | 5.24M | 5.90M | 0.52M | 0.30M |
| Net receivables | 2.88M | 4.78M | 3.02M | 9.13M | 12.35M |
| Inventory | 0.00M | 0.59M | 1.98M | 0.19M | 0.64M |
| Accounts payable | 0.53M | 0.54M | 0.68M | 0.14M | 0.04M |
| Accumulated other comprehensive income | -1.69M | -0.29M | 0.14M | 0.80M | 2.40M |
| Non current assets total | 7.35M | 7.18M | 5.71M | 15.91M | 9.01M |
| Capital lease obligations | 0.03M | 0.06M | 0.81M | 1.70M | 0.20M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.67M | -1.81M | -3.75M | -3.35M | 0.82M |
| Change to liabilities | - | - | - | 0.00M | -0.37M |
| Total cashflows from investing activities | -0.83M | -1.81M | -3.75M | - | -4.02M |
| Total cash from financing activities | 0.00M | 3.84M | 0.00M | 1.85M | 0.00M |
| Change to operating activities | - | - | - | - | 1.11M |
| Net income | -6.31M | -0.27M | -11.31M | -2.82M | 0.24M |
| Change in cash | 0.26M | 0.29M | -3.97M | -2.39M | -1.16M |
| Begin period cash flow | 7.84M | 7.55M | 11.52M | 13.91M | 15.07M |
| End period cash flow | 8.10M | 7.84M | 7.55M | 11.52M | 13.91M |
| Total cash from operating activities | 0.85M | -1.47M | 0.05M | -0.66M | 2.86M |
| Issuance of capital stock | 0.00M | 3.84M | 0.00M | 1.85M | 0.00M |
| Depreciation | 0.32M | 0.43M | 0.92M | 0.73M | 0.70M |
| Other cashflows from investing activities | - | 0.28M | 1.81M | - | -0.39M |
| Change to inventory | 0.60M | -0.01M | -0.41M | -0.19M | 2.01M |
| Change to account receivables | 1.17M | -2.32M | 2.79M | 1.08M | -0.10M |
| Other cashflows from financing activities | - | - | -3.75M | -3.35M | -4.02M |
| Change to netincome | - | - | - | 1.38M | 0.39M |
| Capital expenditures | 0.15M | 3.05M | 0.84M | 1.86M | 1.80M |
| Change in working capital | 1.82M | -2.00M | 2.69M | 0.17M | 1.53M |
| Stock based compensation | 3.71M | 0.11M | 0.14M | 0.16M | 0.21M |
| Other non cash items | 5.10M | -0.03M | 8.35M | 0.96M | 1.52M |
| Free cash flow | 0.69M | -4.52M | -0.79M | -2.52M | 1.06M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ZCMD Zhongchao Inc |
-0.03 2.58% |
0.95 | - | - | 0.57 | 0.35 | 3.07 | 107.07 |
| VEEV Veeva Systems Inc Class A |
-4.88 1.60% |
299.89 | 43.49 | 29.59 | 12.48 | 5.79 | 10.39 | 33.41 |
| PMCUF Pro Medicus Limited |
0.68 0.48% |
142.50 | 64.90 | 90.91 | 49.11 | 38.05 | 65.12 | 83.47 |
| TEM Tempus AI, Inc. Class A Common Stock |
-4.81 6.06% |
74.62 | - | - | 8.68 | 25.39 | 8.33 | - |
| MTHRY M3 Inc |
-0.07 1.22% |
5.66 | 31.84 | 26.25 | 0.05 | 4.60 | 0.04 | 0.12 |
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.
| Name | Title | Year Born |
|---|---|---|
| Mr. Weiguang Yang | Founder, Chairman, Pres & CEO | 1982 |
| Ms. Pei Xu | CFO, Sec. & Director | 1982 |
| Ms. Shuang Wu | Chief Operating Officer | 1983 |
| Mr. Baoqian Tian | Chief Sales Officer | 1984 |
| Mr. Xuejun Chen | Chief Medical Officer | 1978 |
| Mr. Weiguang Yang | Founder, Chairman, President & CEO | 1982 |
| Ms. Pei Xu | CFO, Secretary & Director | 1982 |
| Mr. Xuejun Chen | Chief Medical Officer | 1979 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.